ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1516

The Value of Renal Biopsy at Lower Levels of Proteinuria in Patients Enrolled in the Lupus Accelerating Medicines Partnership

Philip Carlucci1, Kristina Deonaraine1, Andrea Fava2, Jessica Li3, David Wofsy4, Judith James5, Chaim Putterman6, Betty Diamond7, Derek Fine8, Jose Monroy-Trujillo8, Kristin Haag8, William Apruzzese9, H. Michael Belmont10, Peter Izmirly11, Sean Connery12, Fernanda Payan-Schober12, Richard Furie13, Celine Berthier14, Maria Dall'Era15, Kerry Cho16, Diane Kamen17, Kenneth Kalunian18, The Accelerating Medicines Partnership in SLE Network19, Michelle Petri20 and Jill Buyon21, 1New York University School of Medicine, New York, 2Johns Hopkins, Baltimore, 3Johns Hopkins University, Baltimore, MD, 4University of California San Francisco, San Francisco, CA, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Albert Einstein College of Medicine, Bronx, NY, 7Northwell Health, Hartford, 8Johns Hopkins University, Baltimore, 9., Boston, 10NYU School of Medicine, New York, NY, 11Department of Medicine, New York University School of Medicine, New York, NY, 12Texas Tech University Health Sciences Center, Lubbock, 13Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 14University of Michigan, Ann Arbor, 15Division of Rheumatology, University of California, San Francisco, CA, 16University of California San Francisco, San Francisco, 17Medical University of South Carolina, Charleston, SC, 18School of Health Sciences, University of California, La Jolla, 19Multiple Institutions, Multiple Cities, 20Johns Hopkins University School of Medicine, Baltimore, 21Department of Medicine, NYU School of Medicine, New York, NY

Meeting: ACR Convergence 2020

Keywords: Lupus nephritis, Renal, Response Criteria, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Session Title: SLE – Diagnosis, Manifestations, & Outcomes III: Lupus Nephritis (1512–1516)

Session Type: Abstract Session

Session Time: 4:00PM-4:50PM

Background/Purpose: Lupus nephritis continues to be the complication with the highest standardized mortality ratio in Systemic Lupus Erythematosus (SLE), and a late diagnosis associates with worse outcomes. Clinicians traditionally rely on proteinuria to drive decisions regarding renal biopsy and subsequent management.  Since threshold levels for such determinations are variable but critically important, this study leveraged  the well-phenotyped multi-center multi- racial Accelerating Medicines Partnership (AMP) lupus nephritis cohort, to address whether  urine protein to creatinine ratios (UPCR) between .5 and 1 differ from higher ratios with regard to clinical, serologic and histologic variables.

Methods: 239 patients fulfilling ACR or SLICC criteria for SLE with a random or 24 hr uPCR > or = .5 and histologic biopsy Class III, IV, V, or mixed were consecutively enrolled in AMP at the time of renal biopsy and demographics, clinical history, medications,  disease activity as assessed by the hybrid  SELENA-SLEDAI were recorded. Patients with biopsy Classes I, II and VI were ineligible.  Patients were followed at 3, 12, 26 and 52 weeks.

Results: At baseline, 38 patients had a UPCR < 1 (A), 113 had a UPCR 1-3 (B) , and 88 had a UPCR > 3 (C). There were 14 additional patients with UPCR < 1, and 11 patients with UPCR > 1 who had biopsy class I or II.   In group A, there were significantly more male patients (44% A; 23% B; 26% C, p=0.012) with no differences in age, race or ethnicity. Neither the SLEDAI nor serologic parameters (anti-dsDNA, C3, or C4) distinguished among the groups.  Those in group C had a significantly increased creatinine and decreased hemoglobin and albumin compared to the other two groups (Table 1). Patients in group A trended toward having an increased frequency of proliferative histology (Table 2).  This trend was not observed when considering patients for whom this was their first biopsy, but was significant for repeat biopsy patients (56% A; 41% B; 24% C, p=0.03). The activity index was independent of UPCR regardless of biopsy number.  However, those in group C had a significantly higher chronicity index than those with lower UPCR. This correlation was shown for patients with a repeat biopsy (r=0.2299, p=0.003) but not first biopsy patients (r=0.0891, p=0.45). Although medications did not differ at baseline among the groups, at 12 weeks, for each group significantly more patients were taking Mycophenolate Mofetil than at the time of biopsy  (Table 3).

Conclusion: A significant proportion of both first and recurrent biopsies in patients with a UPCR < 1  have proliferative histology and accompanying  activity scores  similar to that of patients with nephrotic range proteinuria. These results support renal biopsy at thresholds lower than a UPCR of 1 since histologic findings can inform therapeutic decisions.

Table 1: Baseline lupus activity by UPCR group.

Table 2: Biopsy characteristics by UPCR group.

Table 3: Comparison of medications at baseline and 12 weeks for each UPCR group


Disclosure: P. Carlucci, None; K. Deonaraine, None; A. Fava, None; J. Li, None; D. Wofsy, GlaxoSmithKline, 9, Novartis, 9, Principia, 5; J. James, None; C. Putterman, Equillium, 1, 2; B. Diamond, None; D. Fine, GSK, 5; J. Monroy-Trujillo, None; K. Haag, None; W. Apruzzese, None; H. Belmont, Exagen, 5; P. Izmirly, GSK, 5; S. Connery, None; F. Payan-Schober, None; R. Furie, AstraZeneca/MedImmune, 2, 5; C. Berthier, None; M. Dall'Era, Janssen, 5, AstraZeneca, 5; K. Cho, None; D. Kamen, None; K. Kalunian, AstraZeneca, 2, 5, AbbVie, 2, 5, Amgen, 2, 5, Biogen, 2, 5, Bristol-Myers Squibb, 2, 5, Eli Lilly, 2, 5, Equillium, 2, 5, Gilead Sciences, Inc., 2, 5, Genentech, 2, 5, ILTOO, 2, 5, Janssen, 2, 5, Lupus Research Alliance, 2, 5, Nektar, 2, 5, Pfizer, 2, 5, Roche, 2, 5, Sanford Consortium, 2, 5, Vielabio, 2, 5; T. Accelerating Medicines Partnership in SLE Network, None; M. Petri, AbbVie, 5, Amgen, 5, AstraZeneca, 2, 5, BMS, 5, Decision Resources, 5, GSK, 2, 5, INOVA, 5, IQVIA, 5, Janssen, 5, Eli Lilly, 2, 5, Merck EMD Serono, 5, Sanofi Japan, 5, Thermofisher, 5, UCB, 5, Exagen, 2; J. Buyon, None.

To cite this abstract in AMA style:

Carlucci P, Deonaraine K, Fava A, Li J, Wofsy D, James J, Putterman C, Diamond B, Fine D, Monroy-Trujillo J, Haag K, Apruzzese W, Belmont H, Izmirly P, Connery S, Payan-Schober F, Furie R, Berthier C, Dall'Era M, Cho K, Kamen D, Kalunian K, Accelerating Medicines Partnership in SLE Network T, Petri M, Buyon J. The Value of Renal Biopsy at Lower Levels of Proteinuria in Patients Enrolled in the Lupus Accelerating Medicines Partnership [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-value-of-renal-biopsy-at-lower-levels-of-proteinuria-in-patients-enrolled-in-the-lupus-accelerating-medicines-partnership/. Accessed July 4, 2022.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-value-of-renal-biopsy-at-lower-levels-of-proteinuria-in-patients-enrolled-in-the-lupus-accelerating-medicines-partnership/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies